TScan Therapeutics, Inc. Common Stock (TCRX) Stock Price, Quote & AI Analysis
Live TCRX stock price, real-time charts, AI-powered analysis, technical analysis, earnings insights, and market sentiment for TScan Therapeutics, Inc. Common Stock.
TradeVae provides AI-driven analysis and real-time market intelligence for TScan Therapeutics, Inc. Common Stock (TCRX), including price action, technical indicators, earnings performance, analyst sentiment, and risk-aware market context.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
TScan Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
TScan Therapeutics, Inc. Common Stock Overview
Company information
Company Overview
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Company Details
Technical Indicators
Key technical analysis metrics and indicators
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
TScan Therapeutics, Inc. Common Stock Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...